Skip to content
DataLookout
Menu

NCT05884333

Cord Blood Transplant in Adults With Blood Cancers

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 6 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words
    • Enrollment closed, study ongoing
    • Final enrollment: 17 participants (planned 54)
    • Site details revised
  2. Minor Site contact updatedv8
  3. Study Identification, Study Status, Oversightv6
  4. Notable Eligibility criteria shortened, about 60 words
    • Study sites: 7 to 1
    v5
  5. Notable Eligibility criteria expanded, about 33 wordsv4
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall survival (OS)
Timeframe: 1 year post transplant

Secondary (1)

Time to neutrophil engraftment

Arms and interventions

Cord Blood TransplantExperimental

Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.

Drugs: Conditioning Chemotherapy

Biologicals: Cord blood graft

Sites

1 site in 1 country

  • Memorial Sloan Kettering Cancer CenterNew York, New York, United States